| Name | Title | Contact Details |
|---|---|---|
Anne-Marie Tucker |
Chief Technology Officer | Profile |
Since opening its doors in 1957, Southeast Health has provided for the changing healthcare needs of the growing communities it serves which includes about 600,000 residents neighboring communities and counties of Southeast Alabama, Southwest Georgia and the Florida Panhandle. Our progress represents the culmination of distinguished service by dedicated board members, physicians, employees and volunteers, and a supportive community. It takes more than technology and a modern facility to treat people. It takes a team of dedicated, well-trained professionals to continually deliver quality healthcare. Employing about 2,500, Southeast Health is recognized as one of the largest employers in the region and is proud of its reputation of providing a positive and responsive work environment. Southeast Health`s medical staff consists of more than 225 active members and just over 400 total members either board certified or board prepared in specialties representing virtually every area of medicine. Through innovation and sustained performance, Southeast Health, a 420-bed regional referral center, has achieved the reputation of providing the best diagnostic, clinical, surgical and patient care services available in the region.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
World Industries is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dynamic Healthcare Systems Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Irvine, CA. To find more information about Dynamic Healthcare Systems Inc., please visit www.dynamichealthsys.com
We would love to welcome you to VillaSport - the only place where fitness, family and community all come together.